These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 10585005)

  • 41. Responses to docetaxel plus vinorelbine in metastatic breast cancer patients failing high-dose chemotherapy.
    Andres R; Mayordomo JI; Isla D; Marti JL; Escudero P; Filipovich E; Saenz A; Alvarez I; Polo E; Tres A
    Br J Cancer; 2002 Mar; 86(6):1017-8. PubMed ID: 11953839
    [No Abstract]   [Full Text] [Related]  

  • 42. Exisulind in combination with docetaxel inhibits growth and metastasis of human lung cancer and prolongs survival in athymic nude rats with orthotopic lung tumors.
    Chan DC; Earle KA; Zhao TL; Helfrich B; Zeng C; Baron A; Whitehead CM; Piazza G; Pamukcu R; Thompson WJ; Alila H; Nelson P; Bunn PA
    Clin Cancer Res; 2002 Mar; 8(3):904-12. PubMed ID: 11895925
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Significant growth inhibition of human lung cancer cells both in vitro and in vivo by the combined use of a selective cyclooxygenase 2 inhibitor, JTE-522, and conventional anticancer agents.
    Hida T; Kozaki K; Ito H; Miyaishi O; Tatematsu Y; Suzuki T; Matsuo K; Sugiura T; Ogawa M; Takahashi T; Takahashi T
    Clin Cancer Res; 2002 Jul; 8(7):2443-7. PubMed ID: 12114451
    [TBL] [Abstract][Full Text] [Related]  

  • 44. New drug and multimodality combinations in the treatment of advanced non--small cell lung cancer.
    Kawahara M; Kris MG; Green M; Kunitoh H
    Semin Oncol; 2001 Jun; 28(3 Suppl 9):1-4. PubMed ID: 11441408
    [No Abstract]   [Full Text] [Related]  

  • 45. Clinical trials of new anticancer agents in recent years in China.
    Sun Y
    Gan To Kagaku Ryoho; 2002 Feb; 29 Suppl 1():86-7. PubMed ID: 11890120
    [No Abstract]   [Full Text] [Related]  

  • 46. [Clinical trials of vnorelbine in breast cancer--its scientific usefulness and development history until regulatory approval].
    Tominaga T
    Gan To Kagaku Ryoho; 2006 Apr; 33(4):541-7. PubMed ID: 16612169
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Second-line chemotherapy for non-small cell lung cancer: is more better or just simply more?
    Shepherd FA
    Lung Cancer; 2002 Jun; 36(3):309-11. PubMed ID: 12009243
    [No Abstract]   [Full Text] [Related]  

  • 48. Single-agent chemotherapy for the treatment of elderly patients with advanced non-small-cell lung cancer: what is the best drug?
    Gridelli C; Maione P; Rossi A
    J Clin Oncol; 2007 Apr; 25(11):1444-5; author reply 1446. PubMed ID: 17416868
    [No Abstract]   [Full Text] [Related]  

  • 49. Multiple myeloma emerging after chemotherapy for non-small-cell lung cancer.
    Marinopoulos S; Skorda L; Karatapanis S; Rasidakis A
    Med Oncol; 2008; 25(4):415-8. PubMed ID: 18345519
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Nitroglycerin shows promise in lung cancer.
    Mayor S
    Lancet Oncol; 2006 Mar; 7(3):203. PubMed ID: 16538789
    [No Abstract]   [Full Text] [Related]  

  • 51. Docetaxel vs. vinorelbine in elderly patients with advanced non-small-cell lung cancer.
    Kurishima K; Kagohashi K; Ishikawa H; Satoh H
    Clin Lung Cancer; 2012 Sep; 13(5):396; author reply 397. PubMed ID: 22484151
    [No Abstract]   [Full Text] [Related]  

  • 52. Trials of vinorelbine and docetaxel in the treatment of advanced non small-cell lung cancer.
    Miller VA
    Clin Lung Cancer; 2000 Apr; 1 Suppl 1():S24-6. PubMed ID: 14725739
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Second-line chemotherapy in non-small cell lung cancer].
    Souquet PJ
    Rev Pneumol Clin; 2004 Nov; 60(5 Pt 2):3S57-9. PubMed ID: 15536355
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Response rate as an endpoint for evaluating new cytotoxic agents in phase II trials of non-small-cell lung cancer.
    Sekine I; Kubota K; Nishiwaki Y; Sasaki Y; Tamura T; Saijo N
    Ann Oncol; 1998 Oct; 9(10):1079-84. PubMed ID: 9834819
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Chemotherapy for patients with hormone-refractory prostate cancer.
    Joly F; Tannock IF
    Ann Oncol; 2004 Nov; 15(11):1582-4. PubMed ID: 15520057
    [No Abstract]   [Full Text] [Related]  

  • 56. [Effect of the association of antimitotic agents on cell lines of human adenocarcinoma].
    Garcia P; Braguer D; Carles G; Briand C
    Bull Cancer; 1994 Oct; 81(10):900-2. PubMed ID: 7734776
    [No Abstract]   [Full Text] [Related]  

  • 57. Minimize toxicity or preserve efficacy? A delicate trade-off in the management of older patients with lung cancer.
    Owonikoko TK; Ramalingam SS
    J Clin Oncol; 2015 Feb; 33(6):534-6. PubMed ID: 25584000
    [No Abstract]   [Full Text] [Related]  

  • 58. American Society of Clinical Oncology--42nd annual meeting. Current approaches to lung cancer therapy. 2-6 June 2006, Atlanta, GA, USA.
    Chan D; Cleverley J
    IDrugs; 2006 Aug; 9(8):523-5. PubMed ID: 16871454
    [No Abstract]   [Full Text] [Related]  

  • 59. Industry corner: perspectives and controversies - The challenges of patient access to new medicines.
    Gann CN; Morsli N; Kaiser R
    Ann Oncol; 2017 Mar; 28(3):658-663. PubMed ID: 27831504
    [No Abstract]   [Full Text] [Related]  

  • 60. The fine points of end points: phase II trials in lung cancer.
    Gelmon KA
    Ann Oncol; 1998 Oct; 9(10):1045-6. PubMed ID: 9834815
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.